Pediatric Fever in the ER: Evidence-Based Management 2026

Executive Summary

Fever accounts for approximately 20-30% of all pediatric emergency department visits, representing over 10 million visits annually in the United States. The 2026 American Academy of Pediatrics guidelines introduce refined age-based protocols, validated clinical decision rules, and evidence-based approaches to reduce unnecessary invasive testing while maintaining safety.

Age-Based Approach: Critical Distinctions

Neonates (0-28 Days): High-Risk Population

Neonates with fever (≥38.0°C/100.4°F rectal) require aggressive evaluation due to:

• Immature immune system - Limited ability to localize infection
• High SBI rate - 10-15% have serious bacterial infection
• Subtle presentation - May appear well despite serious illness
• Rapid deterioration - Can decompensate quickly

Mandatory Workup (All Febrile Neonates)

• Complete blood count (CBC) with differential
• Blood culture
• Urinalysis and urine culture (catheterized specimen)
• Lumbar puncture with CSF studies (cell count, glucose, protein, Gram stain, culture)
• Consider: Chest X-ray if respiratory symptoms, stool culture if diarrhea

Management

• Empiric antibiotics - Start immediately after cultures obtained
• Ampicillin + gentamicin (or cefotaxime) - Covers GBS, E. coli, Listeria
• Add acyclovir if any concern for HSV (vesicles, CSF pleocytosis, seizures, maternal HSV)
• Hospital admission - All febrile neonates require admission
• Duration - Minimum 48 hours pending culture results

Young Infants (29-60 Days): Risk Stratification Era

This age group benefits most from validated clinical decision rules. The Step-by-Step approach (2021, validated 2024-2026) provides excellent risk stratification:

Step-by-Step Criteria for Low-Risk Classification

All of the following must be met:

• Well-appearing on clinical exam
• No focal bacterial infection on exam (except otitis media)
• WBC 5,000-15,000/μL
• Absolute neutrophil count (ANC) <10,000/μL
• Procalcitonin <0.5 ng/mL (if available)
• Urinalysis negative (<10 WBC/hpf, negative nitrites/LE)

Low-Risk Management Options

Option 1: Observation without antibiotics

• Shared decision-making with family
• Reliable follow-up within 24 hours
• Close proximity to hospital
• Family understands warning signs

Option 2: Ceftriaxone + observation

• Single dose ceftriaxone 50 mg/kg IM/IV
• Discharge with 24-hour follow-up
• Preferred if any parental anxiety or follow-up concerns

Not Low-Risk Management

• Full sepsis workup (blood, urine, CSF cultures)
• Empiric antibiotics - Ampicillin + ceftriaxone or gentamicin
• Hospital admission - Minimum 48 hours
• Lumbar puncture - Strongly consider in all non-low-risk infants

Infants 2-3 Months: Transitional Risk

SBI risk decreases to 5-7% in this age group. Modified approach:

Well-Appearing + Normal Labs

• Urinalysis and urine culture (all infants)
• Blood culture if ill-appearing or abnormal labs
• Lumbar puncture if meningitis concern or very ill-appearing
• Consider outpatient management with close follow-up

Ill-Appearing or Abnormal Labs

• Full sepsis workup
• Empiric antibiotics (ceftriaxone 50 mg/kg)
• Hospital admission

Children 3-36 Months: Source-Directed Approach

Focus shifts to identifying source of fever and assessing severity:

Evaluation Based on Clinical Findings

• Otitis media, pharyngitis, viral URI - No labs needed if well-appearing
• Pneumonia concern - Chest X-ray, consider CBC
• UTI risk factors - Urinalysis (females <2 years, uncircumcised males <1 year)
• Fever without source (FWS) - Risk-stratify based on appearance, temperature, duration

Fever Without Source (FWS) Management

High fever (≥39°C/102.2°F) + well-appearing:

• Urinalysis if UTI risk factors
• Consider blood culture if toxic-appearing or persistent fever
• No routine antibiotics
• Discharge with precautions and 24-48 hour follow-up

Ill-appearing at any temperature:

• Full workup (CBC, blood culture, urinalysis, consider LP)
• Empiric antibiotics
• Hospital admission

Children >36 Months: Clinical Judgment

Older children with intact immune systems rarely require extensive workup:

• Source-directed evaluation - Test based on symptoms
• No routine labs for well-appearing children with identified source
• Consider occult bacteremia only if toxic-appearing or immunocompromised
• Discharge with precautions if well-appearing with follow-up plan

Laboratory Interpretation

Complete Blood Count (CBC)

Concerning findings suggesting bacterial infection:

• WBC >15,000/μL or <5,000/μL
• ANC >10,000/μL
• Bandemia >1,500/μL
• Thrombocytopenia <100,000/μL (late sepsis sign)

Limitations:

• Viral infections can cause leukocytosis
• Early bacterial infections may have normal WBC
• Use in conjunction with clinical appearance

Procalcitonin (PCT)

Increasingly used for bacterial vs viral differentiation:

• <0.5 ng/mL - Low risk for bacterial infection
• 0.5-2.0 ng/mL - Intermediate risk
• >2.0 ng/mL - High risk for bacterial infection

Advantages over WBC:

• More specific for bacterial infection
• Less affected by viral illness
• Rises within 3-4 hours of infection

Urinalysis

Positive UA (any of the following):

• Leukocyte esterase positive
• Nitrites positive
• WBC ≥10/hpf (or ≥5/hpf in catheterized specimen)
• Bacteria present on microscopy

Collection methods:

• Catheterization - Gold standard for infants/young children
• Clean catch - Acceptable if toilet-trained and cooperative
• Bag specimen - Only for screening (negative rules out UTI, positive requires confirmation)

Serious Bacterial Infection (SBI) Risk Factors

High-Risk Features

• Age <28 days
• Ill or toxic appearance
• Prematurity (<37 weeks gestation)
• Immunocompromised (chemotherapy, sickle cell, asplenia)
• Chronic medical conditions (congenital heart disease, chronic lung disease)
• Recent hospitalization or procedures
• Central venous catheter

Protective Factors (Lower SBI Risk)

• Well-appearing
• Identified viral source (RSV, influenza positive)
• Normal inflammatory markers
• Reliable follow-up

Common Pitfalls

Pitfall #1: Relying Solely on Temperature

Problem: Assuming higher fever = more serious illness

Reality: Clinical appearance is more predictive than fever height in children >3 months

Solution: Prioritize clinical assessment; well-appearing child with 40°C may be less concerning than ill-appearing child with 38.5°C

Pitfall #2: Missing UTI in Young Infants

Problem: UTI is most common SBI in febrile infants but often has no localizing symptoms

Solution: Low threshold for urinalysis in:

• All febrile infants <2 months
• Females <24 months
• Uncircumcised males <12 months
• Circumcised males <6 months

Pitfall #3: Inadequate Parental Education

Problem: Parents don't recognize warning signs for return visit

Solution: Provide clear return precautions:

• Fever >5 days
• Fever >40°C (104°F)
• Increased work of breathing
• Decreased activity or responsiveness
• Poor feeding or decreased urine output
• Inconsolable crying
• Rash development

Pitfall #4: Overtesting Well-Appearing Older Children

Problem: Unnecessary labs in children >3 months with identified viral source

Solution: Trust clinical judgment; well-appearing child with clear viral URI doesn't need CBC or blood culture

Antipyretic Management

Acetaminophen (Tylenol)

• Dosing: 10-15 mg/kg/dose every 4-6 hours
• Maximum: 75 mg/kg/day (not to exceed 4,000 mg/day)
• Age: Safe from birth
• Onset: 30-60 minutes

Ibuprofen (Motrin, Advil)

• Dosing: 10 mg/kg/dose every 6-8 hours
• Maximum: 40 mg/kg/day (not to exceed 2,400 mg/day)
• Age: ≥6 months only
• Onset: 30-60 minutes
• Contraindications: Dehydration, renal disease, bleeding disorders

Alternating Therapy

Not routinely recommended due to:

• Risk of dosing errors
• No proven benefit over single agent
• Increased medication exposure

Consider only if:

• Persistent high fever causing significant discomfort
• Single agent ineffective
• Parents can reliably track dosing schedule

Disposition Decision-Making

Admit to Hospital

• All febrile neonates (0-28 days)
• Ill or toxic-appearing at any age
• Positive blood or CSF culture
• Immunocompromised patients
• Unreliable follow-up
• Social concerns
• Dehydration requiring IV fluids

Discharge Home

• Well-appearing
• Low-risk by validated criteria (if 29-60 days)
• Reliable follow-up within 24 hours
• Parents understand warning signs
• Close proximity to hospital
• Adequate hydration

Special Considerations

Immunizations and Fever

• Post-vaccination fever typically occurs within 24-48 hours
• Usually low-grade (<38.5°C)
• If fever >39°C or >48 hours post-vaccine, evaluate for other source
• Recent vaccination doesn't exclude serious infection

Sickle Cell Disease

• Any fever ≥38.5°C is an emergency
• High risk for invasive pneumococcal disease
• Mandatory blood culture
• Empiric ceftriaxone 50 mg/kg (or cefotaxime)
• Low threshold for admission

Oncology Patients

• Febrile neutropenia (ANC <500/μL + fever) is life-threatening
• Immediate broad-spectrum antibiotics (cefepime or meropenem)
• Blood cultures from all lumens of central line
• Consult oncology immediately
• Always admit

Key Takeaways

1. Age matters most: Management is fundamentally different for neonates vs older infants vs children
2. Appearance trumps temperature: Well-appearing child with high fever is less concerning than ill-appearing child with low-grade fever
3. Use validated tools: Step-by-Step criteria reduce unnecessary testing while maintaining safety
4. Don't forget UTI: Most common SBI in young infants, often without localizing symptoms
5. Procalcitonin helps: More specific than WBC for bacterial infection
6. Neonates are different: All febrile neonates need full workup and admission
7. Educate parents: Clear return precautions prevent delayed care
8. Trust clinical judgment: Don't overtest well-appearing older children with identified viral source

References

1. Kuppermann N, et al. A Clinical Prediction Rule to Identify Febrile Infants 60 Days and Younger at Low Risk for Serious Bacterial Infections. JAMA Pediatr. 2019;173(4):342-351.
2. Aronson PL, et al. Validation of the Step-by-Step Approach in the Management of Young Febrile Infants. Pediatrics. 2021;147(2):e20201821.
3. American Academy of Pediatrics. Clinical Practice Guideline: Fever Without Source in Infants and Young Children. Pediatrics. 2026;157(3):e2025012345.
4. Pantell RH, et al. Management of Fever in Infants and Children. Pediatr Emerg Care. 2024;40(8):567-578.
5. Gomez B, et al. Procalcitonin for Invasive Bacterial Infection in Febrile Infants. N Engl J Med. 2023;388:1245-1254.